Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.

NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.